liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency
University of Gothenburg, Sweden.
ViroPharma SPRL, England.
ViroPharma Inc, Sweden.
University of Gothenburg, Sweden.
Visa övriga samt affilieringar
2014 (Engelska)Ingår i: European Journal of Endocrinology, ISSN 0804-4643, E-ISSN 1479-683X, Vol. 171, nr 3, s. 369-377Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Objective: The objective was to assess the long-term safety profile of dual-release hydrocortisone (DR-HC) in patients with adrenal insufficiency (AI). Design: Randomised, open-label, crossover trial of DR-HC or thrice-daily hydrocortisone for 3 months each (stage 1) followed by two consecutive, prospective, open-label studies of DR-HC for 6 months (stage 2) and 18 months (stage 3) at five university clinics in Sweden. Methods: Sixty-four adults with primary AI started stage 1, and an additional 16 entered stage 3. Patients received DR-HC 20-40 mg once daily and hydrocortisone 20-40 mg divided into three daily doses (stage 1 only). Main outcome measures were adverse events (AEs) and intercurrent illness (self-reported hydrocortisone use during illness). Results: In stage 1, patients had a median 1.5 (range, 1-9) intercurrent illness events with DR-HC and 1.0 (1-8) with thrice-daily hydrocortisone. AEs during stage 1 were not related to the cortisol exposure-time profile. The percentage of patients with one or more AEs during stage 1 (73.4% with DR-HC; 65.6% with thrice-daily hydrocortisone) decreased during stage 2, when all patients received DR-HC (51% in the first 3 months; 54% in the second 3 months). In stages 1-3 combined, 19 patients experienced 27 serious AEs, equating to 18.6 serious AEs/100 patient-years of DR-HC exposure. Conclusions: This long-term prospective trial is the first to document the safety of DR-HC in patients with primary AI and demonstrates that such treatment is well tolerated during 24 consecutive months of therapy.

Ort, förlag, år, upplaga, sidor
BioScientifica , 2014. Vol. 171, nr 3, s. 369-377
Nationell ämneskategori
Klinisk medicin
Identifikatorer
URN: urn:nbn:se:liu:diva-112489DOI: 10.1530/EJE-14-0327ISI: 000343670900015PubMedID: 24944332OAI: oai:DiVA.org:liu-112489DiVA, id: diva2:766714
Anmärkning

Funding Agencies|ViroPharma SPRL, Maidenhead, UK

Tillgänglig från: 2014-11-28 Skapad: 2014-11-28 Senast uppdaterad: 2017-12-05

Open Access i DiVA

fulltext(233 kB)143 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 233 kBChecksumma SHA-512
56c24c1de69540800c92f4312c4c17b6c7fcb4fb6a66fe61696c3e879202d933ba8d399fe20e710f6f77c5e64b2f17b19642fe73b2a76de2afdff02b183ff45c
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Ekman, BertilWahlberg Topp, Jeanette

Sök vidare i DiVA

Av författaren/redaktören
Ekman, BertilWahlberg Topp, Jeanette
Av organisationen
Avdelningen för kardiovaskulär medicinHälsouniversitetetEndokrinmedicinska enheten
I samma tidskrift
European Journal of Endocrinology
Klinisk medicin

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 143 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 214 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf